EN DE
Watch Xenon Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Xenon Pharmaceuticals Inc (XENE) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Xenon Pharmaceuticals Inc, from audited financials.

Price: $39.17. No valuation: the company's figures do not support a reliable fair value right now, so we deliberately show none.
  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA98420N1050

XP Xenon Pharmaceuticals Inc logo Thin data Nov 7, 2026

Xenon Pharmaceuticals Inc

XENE · US
Low debt
Insiders bought $1.7M (6M) · sold $1.2M
Quality 31/100
Weak Growth (revenue 5y −25.3 %/yr in USD)
Negative free cash flow
Trails peers (2/6)
Narrow moat 20/100
Thin data
No fair value
Watch Xenon Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.

Show moreShow less

Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.

In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.

The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.

Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 89
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 25
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $1.7M, most recently on Sep 30, 2026. Over the same period, 4 people sold shares worth $1.2M. Buying cluster

  • BuyIan MortimerPRESIDENT & CEO, Director30,000 shares at $37.38$1.1MSep 30, 2026
  • BuyThomas Patrick KellyChief Financial Officer15,000 shares at $37.32$559,740Sep 30, 2026
  • SaleChristopher John KenneyChief Medical Officer3× since Mar 10, 2026: 11,249 shares, avg. $59.59$670,288Aug 28, 202610b5-1 plan
  • SaleSteven GannonDirector10,000 shares at $64.06$640,600Aug 11, 2026
  • SaleGillian CannonDirector1,190 shares at $53.14$63,237Jun 5, 202610b5-1 plan
  • SaleGary PatouDirector1,322 shares at $53.14$70,251Jun 5, 202610b5-1 plan
  • SaleIan MortimerPRESIDENT & CEO, Director5× since Nov 28, 2025: 353,879 shares, avg. $57.35$20.3MMar 13, 202610b5-1 plan
  • SaleAndrea DiFabioChief Legal Officer2× since Mar 10, 2026: 3,949 shares, avg. $58.45$230,825Mar 13, 202610b5-1 plan

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.3%
Start year 2020 (pandemic). Over 10 years: −7.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−97.3% (2020) → −4,974.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch XENE, get fair value alerts →

Compare Xenon Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Profitability
Return on assets −35.2% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.71× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs XENE
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs XENE
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs XENE
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$53.55 +12% vs XENE
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs XENE
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs XENE
argenx SE ARGX $927.21 $908.40 −2% vs XENE
CSL Limited CSL A$202.04 A$183.04 −9% vs XENE
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs XENE
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs XENE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector

Frequently asked questions

What is the quality score of XENE?
Xenon Pharmaceuticals Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
How solid is the balance sheet of Xenon Pharmaceuticals Inc (XENE)?
Balance-sheet figures for Xenon Pharmaceuticals Inc (as of Nov 7, 2026): return on equity −43.6%, debt of 0.02 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
Which stocks are comparable to Xenon Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Xenon Pharmaceuticals Inc (XENE)?
The closing price on Nov 6, 2026 was $39.17. We carry closing prices from our data provider, not a live tick.

Key figures of Xenon Pharmaceuticals Inc

How large is the market capitalisation of Xenon Pharmaceuticals Inc (XENE)?
The market capitalisation of Xenon Pharmaceuticals Inc is $3.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Xenon Pharmaceuticals Inc (XENE)?
Earnings per share at Xenon Pharmaceuticals Inc are $−4.74. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Xenon Pharmaceuticals Inc (XENE)?
The return on equity (ROE) of Xenon Pharmaceuticals Inc is −43.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xenon Pharmaceuticals Inc (XENE)?
On an EBIT basis the return on assets of Xenon Pharmaceuticals Inc is −25.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Xenon Pharmaceuticals Inc (XENE) generate?
The free cash flow of Xenon Pharmaceuticals Inc is −$280M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Xenon Pharmaceuticals Inc (XENE) hold?
Xenon Pharmaceuticals Inc holds more cash than debt, $191M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Xenon Pharmaceuticals Inc in the live analysis

One click puts Xenon Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.